he has not been called to trial yet. The waiting list is long.
A new press release from Epizyme states that they will not pursue investigating Tazemetostat as monotherapy in synovial sarcoma due to disappointing results:
http://amda-1rbic2.client.shareholder.com/releasedetail.cfm?ReleaseID=1001058